Amarin Strikes $175M Deal With Recordati to Expand Heart Drug VAZKEPA Across 59 European Countries

Author: Benzinga Newsdesk | June 24, 2025 06:02am

Amarin Corporation (NASDAQ:AMRN) today announced that the Company has entered into an exclusive long-term license and supply agreement (the "Agreement") with Recordati S.p.A. ("Recordati") to commercialize VAZKEPA® (icosapent ethyl) across 59 countries, focused in Europe. This Agreement capitalizes on the early-stage success of VAZKEPA in Europe by partnering with Recordati to accelerate the depth and reach of the product for patients at-risk of a cardiovascular event. As a result of the Agreement, Amarin will streamline its global operations, which further strengthens the Company's financial position.

Under the terms of the Agreement:

• Recordati will be responsible for commercialization of VAZKEPA in Europe.
• Amarin will receive:
  • Upfront cash of $25 million and milestone payments totalling up to $150 million contingent upon Recordati achieving predefined annual commercial net sales levels;
  • Supply-based revenues, including royalties for the supply of the product under the terms of the agreement
     

Posted In: AMRN